Provention Bio, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Stock-based consideration in connection with acquisition of product rights (Note 5)
Stock-based consideration in connection with acquisition of product rights (Note 6)
Change in fair value of warrant liability
Amortization of intangible assets
Amortization of premium and discounts on marketable securities
Amortization of debt issuance costs and accretion of debt discount
Non-cash operating lease expense
Depreciation
Depreciation and amortization
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Accounts receivable, net
Inventory, net
Accounts payable
Accrued interest receivable
Accrued expenses and other current liabilities
Other assets
Deferred revenue

Net cash used in operating activities
Investing activities
Purchase of marketable securities
Maturities of marketable securities
Purchase of fixed assets
Product milestone payments
Net cash (used in) provided by investing activities
Financing activities
Issuance of private placement
Proceeds from initial public offering, net
Proceeds from at-the-market stock sales, net
Net proceeds from debt
Proceeds from underwritten public offering, net
Proceeds from stock option exercises
Net cash provided by financing activities

Net increase in cash and cash equivalents
Net change in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Operating cash flows used for operating leases
Right-of-use assets obtained in exchange for new operating lease liabilities
Supplemental disclosure of non-cash financing transactions:
Reclassification of Series A Preferred Stock warrant liability to stockholders' equity
Conversion of Series A Preferred Stock to common stock upon completion of IPO
Reclassification of Series A Preferred Stock warrant liability to stockholders’ equity
Accretion of Series A Convertible Redeemable Preferred Stock
Fair value of warrants issued in connection with debt issuance

Comments